Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE known ✓ | P06276 | 2/20 | 0.46 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.46 |
| ▸ | PDE4A known ✓ | P27815 | 3/20 | 0.45 |
| ▸ | PDE4B known ✓ | Q07343 | 2/20 | 0.45 |
| ▸ | PDE4C known ✓ | Q08493 | 2/20 | 0.45 |
| ▸ | PDE4D known ✓ | Q08499 | 2/20 | 0.45 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.45 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.41 |
| ▸ | P2RY12 known ✓ | Q9H244 | 1/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.45 |
| ▸ | PADI1 | Q9ULC6 | 4/20 | 0.45 |
| ▸ | PADI4 | Q9UM07 | 4/20 | 0.45 |
| ▸ | PADI2 | Q9Y2J8 | 3/20 | 0.45 |
| ▸ | PADI3 | Q9ULW8 | 3/20 | 0.45 |
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11325263 | 1.00 | BCHE (0.46) | BCHEACHECYP26A1PADI1PADI4 | |
| SCHEMBL80453 | 0.99 | BCHE (0.47) | BCHEACHECYP26A1PADI1PADI4 | |
| SCHEMBL562113 | 0.99 | BCHE (0.47) | BCHEACHECYP26A1PADI1PADI4 | |
| SCHEMBL15739025 | 0.98 | BCHE (0.46) | BCHEACHECYP26A1PADI1PADI4 | |
| Hydrochloric Acid SCHEMBL29401063 | 0.91 | CA1 (0.53) | CYP26A1PADI1PADI4PDE4APADI2 | |
| SCHEMBL158087 | 0.90 | CA1 (0.54) | CYP26A1PADI1PADI4PDE4APADI2 | |
| SCHEMBL31206858 | 0.90 | CA1 (0.54) | CYP26A1PADI1PADI4PDE4APADI2 | |
| SCHEMBL16289858 | 0.90 | CA1 (0.54) | CYP26A1PADI1PADI4PDE4APADI2 | |
| SCHEMBL1396385 | 0.90 | BCHE (0.48) | BCHEACHECYP26A1PADI1PADI4 | |
| SCHEMBL15271466 | 0.90 | BCHE (0.48) | BCHEACHECYP26A1PADI1PADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119604537-A | Antibodies that bind to human PAD4 and uses thereof | 百时美施贵宝公司 | 2025-03-11 | — | — | CN | claimed |
| CN-118285483-A | Rolling and kneading raw meat product production method | 山东中粹生态发展有限公司 | 2024-07-05 | — | — | CN | claimed |
| CN-116606904-A | Method for improving stability of trypsin titer determination result for injection | 中国食品药品检定研究院 | 2023-08-18 | — | — | CN | claimed |
| CN-110112512-B | Totally-enclosed metal-carbon dioxide battery and preparation method thereof | 上海大学 | 2022-10-11 | — | — | CN | claimed |
| CN-111760473-A | Composite semipermeable membrane, preparation method and application | 中国石油化工股份有限公司 | 2020-10-13 | — | — | CN | claimed |
| CN-111760472-A | Composite membrane and preparation method and application thereof | 中国石油化工股份有限公司 | 2020-10-13 | — | — | CN | claimed |
| CN-111004832-A | Method for detecting kallidinogenase | 常州千红生化制药股份有限公司 | 2020-04-14 | — | — | CN | claimed |
| CN-110112512-A | Totally enclosed type metal-carbon dioxide battery and preparation method thereof | 上海大学 | 2019-08-09 | — | — | CN | claimed |
| CN-107484895-A | A kind of just term milch goat special feed and preparation method thereof | 山东阳春羊奶乳业有限公司 | 2017-12-19 | — | — | CN | claimed |
| CN-102732548-A | Establishment and application of wheat germ cell-free protein synthesis system for high level expression of snake venom kininogenase | UNIV CHINA AGRICULTURAL | 2012-10-17 | — | — | CN | claimed |
| CN-101407792-B | Preparation of pit viper bioactivity enzyme | XIUHUA GUO | 2010-08-18 | — | — | CN | claimed |
| CN-101407792-A | Preparation of pit viper bioactivity enzyme | XIUHUA GUO (CN) | 2009-04-15 | — | — | CN | claimed |
| US-12559570-B2 | Anti-PAD2 antibody | PHARMA FOODS INTERNATIONAL CO., LTD. (JP) | 2026-02-24 | — | — | US | disclosed |
| US-20250289855-A1 | ANTIMICROBIAL CaNCR PEPTIDE FOLDING VARIANTS | DONALD DANFORTH PLANT SCIENCE CENTER | 2025-09-18 | — | — | US | disclosed |
| EP-3801068-B1 | MODIFIED RAPESEED PROTEIN ISOLATE | DSM IP ASSETS BV (NL) | 2025-07-30 | — | — | EP | disclosed |
| EP-4558529-A1 | ANTIBODIES BINDING TO HUMAN PAD4 AND USES THEREOF | Bristol-Myers Squibb Company (US) | 2025-05-28 | — | — | EP | disclosed |
| US-4246351-A | COMPRISING POROUS ADDITION COPOLYMERS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1981-01-20 | — | — | US | disclosed |
| US-4153687-A | Derivatives, having an inhibitory action against protease and an antiphlogistic action, of the trypsin-kallikrein inhibitor obtained from cattle organs (BPTI), their preparation and their use as medicaments | BAYER AKTIENGESELLSCHAFT (DE) | 1979-05-08 | — | — | US | disclosed |
| US-4118481-A | LYSINE, ARGININE, TYROSINE, PROTEASE INHIBITION | BAYER AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
| US-3940478-A | Proteolytic enzymes as adjuncts to antibiotic prophylaxis of contaminated wounds | SUTURES, INC. (US) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559570-B2 | Anti-PAD2 antibody | PADI2, PADI1, PADI4 | BCHE 2229/4885ACHE 3055/4885PDE4A 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.